MDV3100 vs. abiratetone acetate: the analysts’ perspectives

Some readers may be interested in in reading a commentary by John Carroll on the FierceBiotech web site, where he discusses whether MDV3100 is going to be able to “match up” to abiraterone acetate — always assuming that MDV3100 can also show a survival benefit in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

What’s hot at the AUA annual meeting (Sunday morning)?

So lots of posters and and presentations this morning, but not a lot of actionable information for patients (as far a we could tell). Among the more interesting papers were the following: … READ MORE …

How to get really bad investment advice

As we get closer to the annual meeting of the American Society of Clinical Oncology (ASCO) — to be held at the beginning of June — the investor community is beginning its annual frenzy of speculation about exactly what new information will be presented at the meeting about development stage and marketed drugs. … READ MORE …

For those who want to learn more about new treatments for CRPC

Patients and others with a strong interest in understanding the ways in which new drugs like abiraterone acetate and MDV3100 are likely to change the way we treat advanced forms of prostate cancer might be interested in a webcast based on a satellite symposium held at the recent Genitourinary Cancers Symposium in Orlando. … READ MORE …

Second Phase III clinical trial of MDV3100 in mCRPC

According to a media release issued earlier today, Medivation and Astellas Pharma have enrolled the first patient into a new Phase III clinical trial of MDV3100. … READ MORE …

Media reports about Phase I/II data on MDV3100

There have been numerous media reports about on-line publication of data from a Phase I/II clinical trial of MDV3100 over the past 2 days. … READ MORE …

MDV3100 Phase III trial starts to enroll patients

According to an e-mail from our friends at Us TOO the AFFIRM trial (A study evaluating the eFFicacy and safety of Investigational dRug MDV3100 in men with advanced prostate cancer) has started to enroll patients in the USA. It had started to enroll patients in Europe earlier this month. … READ MORE …

Astellas acquires development rights to MDV3100

According to a media release this morning, the global pharmaceutical company Astellas has licensed rights to commercialize Medivation’s investigational prostate cancer drug MDV3100. … READ MORE …

Medivation starts Phase III trial of MDV3100

According to a media release from Medivation, Inc. earlier today, the company has treated the first patient in a Phase III clinical trial of the novel androgen receptor antagonist MDV3100 in advanced prostate cancer. … READ MORE …

ASCO commentary and update no. 1

On Saturday there were two major prostate cancer sessions and additional poster sessions that included prostate cancer-related material at the annual meeting of the American Society for Clinical Oncology. … READ MORE …

An MDV3100 update

There are several stories on the Web today about a forthcoming article in Science giving data about a phase I/II trial of MDV3100. … READ MORE …

The Thursday news reports: March 19, 2009

There are six new reports in today’s news, of which the most immediately important would seem to be:

  • How men manage their “fear” while on active surveillance
  • “Cancer anxiety” and early use of hormonal therapy
  • Approval for a Phase III clinical trial of MDV3100 … READ MORE …

More from the GU Oncology Symposium — a wrap-up

Looking through my assorted notes from the meeting this morning after getting home late last night, there are four other poster presentations that are worth commenting on very specifically, and then a general comment that I would add. … READ MORE …

In Friday’s research news: December 19, 2008

In the prostate cancer research news today, there are two new developments and a report of another failure. So first the bad news … READ MORE …

MDV3100 in castration-resistant prostate cancer

Medscape has just published an extensive update on the ongoing Phase I/II clinical trial of MDV3100 an investigational androgen-receptor antagonist for use in the treatment of advanced prostate cancer. … READ MORE …